A similar beneficial association was seen in an observational study of semaglutide in 83,825 patients with obesity and 598,803 patients with T2DM over 12 months 112 , as well as in 87,676 new users of GLP-1RAs or DPP-4 inhibitors over 4 years 113
Reviewed submitted version of manuscript: Bydon, Ghaith, Johnson, Akinduro, De Biase, Bon Nieves, Marsh, Atkinson, Spinner
Please also talk with your doctor about prescription-based options and be sure to discuss any supplement interactions if you are on medications
This new medicine uses both GIP and GLP-1 receptors to help control appetite and keep blood sugar levels steady
Evidence Limitations and Unanswered Questions The main evidence limitations for GHK-Cu are uneven human data, formulation differences, limited injectable safety information, small topical skin studies, indirect hair evidence, and uncertain long-term outcomes [2], [6], [7], [8]
10.1007/s12035-016-0118-6 18 ChangL.AlicataD.ErnstT.VolkowN